Dementia in 2014: Towards early diagnosis in Alzheimer disease

Nature Reviews Neurology

Volumn 11, Issue 2, 2015, Pages 69-70

  Nordberg, Agneta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; FLUORINE T808 F 18; FLUORINE THK5105 F 18; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID BRAIN LEVEL; AMYLOID PLAQUE; COGNITION; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; DRUG BRAIN LEVEL; EARLY DIAGNOSIS; HUMAN; NERVE DEGENERATION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RADIOISOTOPE DIAGNOSIS; REVIEW; AGE; DIAGNOSTIC USE; METABOLISM; PATHOLOGY; PROCEDURES; RISK FACTOR; SCINTISCANNING;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK FACTORS; TAU PROTEINS;

EID: 84926199141     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.257     Document Type: Review

References (10)

1. Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 13, 614-629 (2014).
2. Bentzinger, T. L. et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc. Natl Acad. Sci. USA 110, E4502-E4509 (2013).
3. Norton, S. et al. Potential for primary prevention of Alzheimer's disease-an analysis of population-based data. Lancet Neurol. 13, 788-794 (2014).
4. Okamura, N. et al. Non-invasive assessments of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137, 1762-1771 (2014).
5. Chien, D. T. et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J. Alz. Dis. 38, 171-184 (2014).
6. Maruyama, M. et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to controls. Neuron 79, 1094-1098 (2013).
7. Fagan, A. M. et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci. Transl. Med. 5, 226ra30 (2014).
8. Jack, C. R. et al. Age-specific population frequences of cerebral ?-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 13, 997-1005 (2014).
9. Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755-766 (2014).
10. Mormino, E. C. et al. Synergistic effect of ?-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 71, 1379-1385 (2014).